Novo shares rise as HIMS halt sales of some obesity drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Hims and Hers (HIMS) PT Raised to $39 at Truist Securities
February 26, 2025 5:30 AM ESTTruist Securities analyst Jailendra Singh raised the price target on Hims and Hers (NYSE: HIMS) to $39.00 (from $24.00) while maintaining a Hold rating.
The analyst comments "We had a post-quarterly call with HIMS to discuss 4Q24 results, puts and takes in weight loss solution outlook,... More
